<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - NEVIRAPINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>NEVIRAPINE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">HIV infection in combination with other antiretroviral drugs (initial dose)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 200 mg once daily for first 14 days, initial dose titration using &#8216;immediate-release&#8217; preparation should not exceed 28 days; if rash occurs and is not resolved within 28 days, alternative treatment should be sought. If treatment interrupted for more than 7 days, restart using the lower dose of the &#8216;immediate-release&#8217; preparation for the first 14 days as for new treatment.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">HIV infection in combination with other antiretroviral drugs (maintenance dose following initial dose titration if no rash present)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                200 mg twice daily.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                400 mg once daily.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>




      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid modified-release preparation&#8212;no information available; use &#8216;immediate-release&#8217; preparation with caution in moderate impairment and avoid in severe impairment.</p><p>Use with caution in patients with chronic hepatitis B or C (at greater risk of hepatic side effects).</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Manufacturer advises avoid modified-release preparation&#8212;no information available.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li><xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref></li>
            <li>post-exposure prophylaxis</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, diarrhoea, fatigue, fever, granulocytopenia, headache, hepatitis, hypersensitivity reactions (may involve hepatic reactions and rash), nausea, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, vomiting,
              </p>
              <p>
                <strong>uncommon:</strong> Anaemia, arthralgia, myalgia,
              </p>
              <p>
                <strong>notKnown:</strong> Osteonecrosis,
              </p>
        
        
            <section class="advice">
                <h3>Hepatic effects</h3>
              <p>Potentially life-threatening hepatotoxicity including fatal fulminant hepatitis reported usually in first 6 weeks; discontinue permanently if abnormalities in liver function tests accompanied by hypersensitivity reaction (rash, fever, arthralgia, myalgia, lymphadenopathy, hepatitis, renal impairment, eosinophilia, granulocytopenia); suspend if severe abnormalities in liver function tests but no hypersensitivity reaction&#8212;discontinue permanently if significant liver function abnormalities recur; monitor patient closely if mild to moderate abnormalities in liver function tests with no hypersensitivity reaction.</p>
            </section>
            <section class="advice">
                <h3>Rash</h3>
              <p>Rash, usually in first 6 weeks, is most common side-effect; incidence reduced if introduced at low dose and dose increased gradually (after 14 days); Discontinue permanently if severe rash or if rash accompanied by blistering, oral lesions, conjunctivitis, facial oedema, general malaise or hypersensitivity reactions; if rash mild or moderate may continue without interruption but dose should not be increased until rash resolves.</p>
            </section>
            <section class="advice">
                <h3>Osteonecrosis</h3>
              <p>For more information see <xref format="dita" href="#PHP78275" type="bookmark" namespace="/treatment-summaries/hiv-infection">HIV infection</xref>.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="adviceAroundMissedDoses">
              <p>If a dose is more than 8 hours late with the &#8216;immediate-release&#8217; preparation (or more than 12 hours late with the modified-release preparation), the missed dose should not be taken and the next dose should be taken at the usual time.</p>
            </section>
            <section class="generalPatientAdvice">
                <h3>Hypersensitivity reactions</h3>
              <p>Patients or carers should be told how to recognise hypersensitivity reactions and advised to discontinue treatment and seek immediate medical attention if severe skin reaction, hypersensitivity reactions, or symptoms of hepatitis develop.</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Females (at greater risk of hepatic side effects)
          </li>
          <li>
            high CD4 cell count (at greater risk of hepatic side effects)
          </li>
        </ul>
        <ul>
          <li>
            <p>Patients with chronic hepatitis B or C, high CD4 cell count, and women are at increased risk of hepatic side effects&#8212;if plasma HIV-1 RNA detectable, manufacturer advises avoid in women with CD4 cell count greater than 250&#8239;cells/mm<sup>3</sup> or in men with CD4 cell count greater than 400&#8239;cells/mm<sup>3</sup> unless potential benefit outweighs risk.</p>
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
                <h3>Hepatic disease</h3>
              <p>Close monitoring of liver function required during first 18 weeks; monitor liver function before treatment then every 2 weeks for 2 months then after 1 month and then regularly.</p>
            </section>
            <section class="patientParameters">
                <h3>Rash</h3>
              <p>Monitor closely for skin reactions during first 18 weeks.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of NEVIRAPINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76878"><a href="../medicinalForm/PHP76878.html" data-target="#PHP76878" data-action="load">Tablet</a></div>
            <div id="PHP76892"><a href="../medicinalForm/PHP76892.html" data-target="#PHP76892" data-action="load">Modified-release tablet</a></div>
            <div id="PHP76885"><a href="../medicinalForm/PHP76885.html" data-target="#PHP76885" data-action="load">Oral suspension</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
